Journal article

Sofosbuvir/velpatasvir for 12 vs. 6 weeks for the treatment of recently acquired hepatitis C infection.

Gail V Matthews, Sanjay Bhagani, Marc Van der Valk, Juergen Rockstroh, Jordan J Feld, Andri Rauch, Christine Thurnheer, Julie Bruneau, Arthur Kim, Margaret Hellard, David Shaw, Ed Gane, Mark Nelson, Patrick Ingiliz, Tanya L Applegate, Jason Grebely, Phillipa Marks, Marianne Martinello, Kathy Petoumenos, Gregory J Dore Show all

J Hepatol | Published : 2021

DOI: 10.1016/j.jhep.2021.04.056

Abstract

BACKGROUND & AIMS: Shortened duration therapy for acute and recent HCV infection has been shown to be highly effective in several small non-randomised studies with direct-acting antiviral regimens; however, large randomised studies are lacking. METHODS: REACT was an NIH-funded multicentre international, open-label, randomised, phase IV non-inferiority trial examining the efficacy of short course (6-week) vs. standard course (12-week) therapy with sofosbuvir-velpatasvir for recent HCV infection (estimated duration of infection ≤12 months). Randomisation occurred at week 6. The primary endpoint was sustained virological response 12 weeks after treatment end (SVR12) in the intention-to treat (I..

View full abstract

University of Melbourne Researchers

Keywords

React Study Group
Direct-Acting Antivirals
Short Duration
Coordinating Centre
Recently Acquired
Treatment
Protocol Steering Committee
Hcv
Acute
Site Principal Investigators